

Urgent Field Safety Notice

SBN-CPS-2020-009



CPS / ClinChem fully automated

Version 1

November 2020

Sporadic outliers with certain TDM parameters on cobas c 503

Product Name	ONLINE TDM Vancomycin Gen.3 (VANC3), 100T ONLINE TDM Vancomycin Gen.3 (VANC3), 200T ONLINE TDM Gentamicin Gen.2 (GENT2), 100T ONLINE TDM Phenytoin (PHNY2), 100T ONLINE TDM Phenytoin (PHNY2), 200T ONLINE TDM Theophylline (THEO2), 100T ONLINE TDM Phenobarbital (PHNO2), 200T
System	cobas c 503 analytical unit
GMMI / Part No	VANC3 - 08445605190, 08058849190
Device Identifier	GENT2 - 08057770190 PHNY2 - 08445567190, 08058601190 THEO2 - 08253153190 PHNO2 - 08058580190
Production Identifier (Product name/Product code)	VANC3, GENT2, PHNY2, THEO2, PHNO2: all lots
SW Version	n/a
Type of Action	Field Safety Corrective Action

Dear Valued Customer,

Description of Situation

We would like to inform you that we have received three customer complaints regarding low Quality Control (QC) recoveries of Therapeutic Drug Monitoring (TDM) parameters on the **cobas c 503** analytical unit. The first QC run resulted in a too low recovery while the repeat or second QC recovery is within range.

Internal experiments have confirmed that for the TDM assays Vancomycin, Gentamicin, Phenytoin, Theophylline and Phenobarbital inaccurately low results were observed either in the first or the second determination after the system had not pipetted reagent from the c pack green (reagent cassette) for a time period longer than one hour. Subsequent determinations from these assays were not affected unless an additional time period of more than one hour without pipetting has elapsed. Two consecutive outliers have never been observed.

Sporadic outliers with certain TDM parameters on cobas c 503



As a potential root cause, we have identified dried reagent in the piercing conus of the c pack green onboard the system. According to internal investigations, a transfer of residual dried reagent from the piercing conus into the reagent-sample mixture leads to the observed outliers for TDM tests. Specifically, competitive assay formats as used in the mentioned TDM assays are sensitive to such an incident. Testing of assays from other indications during our investigations revealed that the issue is limited to the TDM assays mentioned above.

Actions to be taken by Roche Diagnostics

An additional functionality in the analyzer software is under evaluation. This new function is planned to enable cleaning of the c pack green conus using the reagent probes. The software function will be automatically activated when a determination is requested from an affected c pack green and when a predefined time interval after the last pipetting event from that c pack green is exceeded.

After the software evaluation and before rollout of this software feature, customers will be informed by an update of this FSN.

Actions to be taken by the customer/user

While a permanent solution is under investigation, the procedures described below have to be followed in order to maintain the ability to test the five affected TDM parameters on the **cobas c 503** analytical unit. Since conditions are different across customer laboratories, as well as over the working day, we would like to list several potential workable solutions.

The Quality Control (QC) is an essential criterion to decide whether testing should proceed or not. In the described workarounds, the QC serves as a measure that is able to prevent that the incident affects diagnostic TDM tests. A low QC recovery indicates that the event might have occurred and a repetition of the QC is required before patient samples are measured.

QC-timeout triggered masking

In the interest of a consistent workflow in the laboratory, the following procedure requiring additional QC protocols is recommended:

- Set QC-timeout for the affected TDM assays to 1 hour.
- Activate the QC-timeout-triggered masking of patient sample runs.
- Run all QC levels from high to low concentration levels, e.g. 04521536190 TDM Control Set.
- An assay, e.g. VANC3, will be unmasked for the patient sample only if QC results are within range.
- Run patient samples.
- Please ensure that the timeout of 1 hour is not missed. Otherwise a patient sample will be masked for the assay (e.g. VANC3), not measured and be routed to the sample buffer.
- Samples collected in the sample buffer might be measured in batch mode after performing a new QC.
- QC-timeout triggered masking is also required when the affected assays are run in batch mode.

If the timeout triggered masking does not fit the laboratory workflow, we recommend proceeding as follows:

Duplicate TDM testing in one run

This workaround does not require additional QC protocols as samples are tested twice for the affected TDM parameter. The usual QC procedures in the laboratory can be maintained, e.g. morning QC.

Sporadic outliers with certain TDM parameters on cobas c 503



- The assay should be ordered in duplicate from the LIS (recommended, if the on-site LIS is capable doing so) or in the **cobas pro** user interface.
- No additional setting is required on the **cobas pro (c 503)**.
- Since the adverse event creates only inaccurately low results, the higher TDM test result is the correct one and should be selected and reported.
- The duplicate testing allows the customer to avoid additional QC runs prior to the TDM testing.

Note:

In this case, no general recommendations with respect to the review and follow up of results are given, taking into account different possible scenarios. Any specific questions raised by the users should be addressed individually, considering all relevant clinical information.

Communication of this Field Safety Notice (if appropriate)

This notice must be passed on to all those who need to be aware within your organization where the devices have been distributed/supplied (if appropriate).

Please transfer this notice to other organizations/individuals on which this action has an impact.

Please maintain awareness of this notice and resulting action for an appropriate period to ensure the effectiveness of the corrective action.

The following statement is mandatory in FSNs for EEA countries but is not required for the rest of the World:

Include if applicable: The undersigned confirms that this notice has been notified to the appropriate Regulatory Agency.

We apologize for any inconvenience this may cause and hope for your understanding and your support.

<closing salutations>,

Contact Details

To be completed locally:

Name

Title

Company Name

Address

Tel. +xx-xxx-xxxx xxxx

Email name@roche.com